All Stories

  1. Novel processes to obtain pneumococcal surface proteins for vaccines
  2. Optimization of methods for isolation and purification of outer membrane vesicles (OMVs) from Neisseria lactamica
  3. In-silico and experimental analysis of Klebsiella pneumoniae fimbriae subunits for vaccine development
  4. In-Silico and in Vivo Tools to Select Vaccine Candidates Against Klebsiella Pneumoniae Infection from its Fimbrial Components
  5. Comparison Between Simple Batch and Fed-Batch Bioreactor Cultivation of Recombinant BCG
  6. The Toxin of VapBC-1 Toxin-Antitoxin Module from Leptospira interrogans Is a Ribonuclease That Does Not Arrest Bacterial Growth but Affects Cell Viability
  7. Novel method for production and purification of untagged pneumococcal surface protein A from clade 1
  8. Liposome-based dry powder vaccine immunization targeting the lungs induces broad protection against pneumococcus
  9. Influence of the mRNA initial region on protein production: a case study using recombinant detoxified pneumolysin as a model
  10. A comprehensive method for modeling and simulating ion exchange chromatography of complex mixtures
  11. Peptide linker increased the stability of pneumococcal fusion protein vaccine candidate
  12. Pneumococcal Surface Protein A-Hybrid Nanoparticles Protect Mice from Lethal Challenge after Mucosal Immunization Targeting the Lungs
  13. ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification
  14. Robust Immune Response Induced by Schistosoma mansoni TSP-2 Antigen Coupled to Bacterial Outer Membrane Vesicles
  15. Optimization of Expression and Purification of Schistosoma mansoni Antigens in Fusion with Rhizavidin
  16. Strategies for the Production of Soluble Interferon-Alpha Consensus and Potential Application in Arboviruses and SARS-CoV-2
  17. High stabilization and hyperactivation of a Recombinant β-Xylosidase through Immobilization Strategies
  18. Evaluation of polymer choice on immunogenicity of chitosan coated PLGA NPs with surface-adsorbed pneumococcal protein antigen PspA4Pro
  19. Development of recombinant human granulocyte colony-stimulating factor (nartograstim) production process in Escherichia coli compatible with industrial scale and with no antibiotics in the culture medium
  20. Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced in Escherichia coli
  21. Cost analysis based on bioreactor cultivation conditions: Production of a soluble recombinant protein using Escherichia coli BL21(DE3)
  22. Improvement of the production process for a new vaccine against pneumococcal diseases
  23. Modeling and simulation of anion exchange chromatography for purification of proteins in complex mixtures
  24. Optimization and scale-up production of Zika virus ΔNS1 in Escherichia coli: application of Response Surface Methodology
  25. Progress in mucosal immunization for protection against pneumococcal pneumonia
  26. Children as curators: how to incorporate young visitors’ voices into the elaboration and evaluation of a microbiology exhibition
  27. A new vector for heterologous gene expression in Escherichia coli with increased stability in the absence of antibiotic
  28. Learning about Microorganisms in Childhood: Four- to Six-Year-Old Children’s Voice in Kindergartens and Museums
  29. Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection
  30. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies
  31. IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine
  32. Production and purification of an untagged recombinant pneumococcal surface protein A (PspA4Pro) with high-purity and low endotoxin content
  33. DEVELOPMENT OF A NEW PROCESS FOR PURIFICATION OF CAPSULAR POLYSACCHARIDE FROM Streptococcus pneumoniae SEROTYPE 14
  34. Recombinant protein production by engineered Escherichia coli in a pressurized airlift bioreactor: A techno-economic analysis
  35. ON-LINE MONITORING OF BIOMASS CONCENTRATION BASED ON A CAPACITANCE SENSOR: ASSESSING THE METHODOLOGY FOR DIFFERENT BACTERIA AND YEAST HIGH CELL DENSITY FED-BATCH CULTURES
  36. Pulmonary dry powder vaccine of pneumococcal antigen loaded nanoparticles
  37. Capsular polysaccharide production by Streptococcus pneumoniae serotype 1: from strain selection to fed-batch cultivation
  38. PRODUÇÃO DE UMA MOLÉCULA RECOMBINANTE HÍBRIDA DE DUAS PROTEÍNAS DE Streptococcus pneumoniae: PspA94-PdT
  39. Improved capsular polysaccharide production by Streptococcus pneumoniae serotype 14 using continuous cultivation
  40. A supervision and control tool based on artificial intelligence for high cell density cultivations
  41. Development of a whole cell pneumococcal vaccine: BPL inactivation, cGMP production, and stability
  42. On-line prediction of the feeding phase in high-cell density cultivation of rE. coli using constructive neural networks
  43. Conjugation of Polysaccharide 6B from Streptococcus pneumoniae with Pneumococcal Surface Protein A: PspA Conformation and Its Effect on the Immune Response
  44. High cell density co-culture for production of recombinant hydrolases
  45. Intensification of high cell-density cultivations of rE. coli for production of S. pneumoniae antigenic surface protein, PspA3, using model-based adaptive control
  46. Quantification of capsular polysaccharide of Streptococcus pneumoniae serotype 14 in culture broth samples
  47. Development of production and purification processes of recombinant fragment of pneumococcal surface protein A in Escherichia coli using different carbon sources and chromatography sequences
  48. Humoral immune response of a pneumococcal conjugate vaccine: Capsular polysaccharide serotype 14—Lysine modified PspA
  49. Robust artificial intelligence tool for automatic start-up of the supplementary medium feeding in recombinant E. coli cultivations
  50. Production and purification of recombinant fragment of pneumococcal surface protein A (PspA) in Escherichia coli
  51. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis
  52. Pneumococcal whole-cell vaccine: optimization of cell growth of unencapsulated Streptococcus pneumoniae in bioreactor using animal-free medium
  53. Protection induced by pneumococcal surface protein A (PspA) is enhanced by conjugation to a Streptococcus pneumoniae capsular polysaccharide
  54. A Heuristic Search for Optimal Parameter Values of Three Biokinetic Growth Models for Describing Batch Cultivations of Streptococcus Pneumoniae in Bioreactors
  55. An Empirical Investigation of the Use of a Neural Network Committee for Identifying the Streptococcus Pneumoniae Growth Phases in Batch Cultivations
  56. Strategies for production of polysaccharide for pneumococcal conjugate vaccine
  57. Accumulation of organic acids in cultivations of Neisseria meningitidis C
  58. Industrial purification method of the polysaccharide to be used as vaccine
  59. Optimization of medium and cultivation conditions for capsular polysaccharide production by Streptococcus pneumoniae serotype 23F
  60. An associated process for the purification of immuno globulin G, catalase, superoxide dismutase and albumin from haemolysed human placenta blood
  61. Albumin purification from human placenta
  62. Crystallization and preliminary X-ray diffraction studies of human catalase